HK Stock Market Move | XUANZHUBIO-B(02575) rose more than 18% in early trading. The Phase III clinical trial results of Piloselyl BRIGHT-2 were published in the top journal of Xi'An International Medical Investment.

XUANZHUBIO-B (02575) rose by more than 18% in the morning session, as of the deadline, it rose by 11.85%, closing at HK$40.58, with a turnover of HK$18.864 million. In terms of news, on March 24th, XUANZHUBIO-B announced that the final analysis results of the Phase III BRIGHT-2 clinical study of the company's independently developed novel CDK2/4/6 inhibitor Bireociclib have been officially published online in the top international medical journal "JAMA Oncology" (Impact Factor 20.1). The BRIGHT-2 study is a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial conducted in China, aiming to evaluate the efficacy and safety of Bireociclib in combination with fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) -) advanced breast cancer after prior endocrine therapy. The study was led by Academician Xu Binghe from the Cancer Hospital of the Chinese Academy of Medical Sciences and conducted in 64 hospitals nationwide. The company previously published the interim analysis results of the BRIGHT-2 study in the journal "Nature Communications" in April 2025. The results published this time are the final analysis results, with an additional 11 months of follow-up added on the basis of the interim analysis, the median follow-up time has been extended to 19 months, further demonstrating the maturity and robustness of Bireociclib in terms of survival benefits.